U.S. pharma large copyright scrapped two experimental weight loss products final yr—a after-every day capsule, lotiglipron, because of elevated liver enzymes along with a twice-every day tablet, danuglipron, due to powerful Uncomfortable side effects—but CEO Albert Bourla has said th